Angina Pectoris, Coronary Artery Disease, Myocardial Infarction
Conditions
Keywords
CABG, Coronary artery bypass surgery, Coronary artery bypass grafting, Coronary surgery, Myocardial infarction, Coronary artery disease, Off-pump, EuroSCORE
Brief summary
The E-CABG registry is a multicenter, European registry collecting data on the preoperative characteristics, treatment strategies and outcome of patients undergoing isolated coronary artery bypass grafting (CABG).
Detailed description
Improvements in the surgical treatment of coronary artery disease are possible only when implementation of current methods and development of new methods are based on the solid ground of large and reliable clinical data. Furthermore, clinical findings assume even more significance when detected in study populations from different institutions with heterogeneous referral pathways, baseline clinical characteristics and perioperative treatment strategies. The rationale of this European multicenter study is therefore to prospectively collect data on baseline characteristics, operative and anesthesiological methods and postoperative outcome of patients undergoing CABG in eleven cardiac surgery centers from five European countries. This multicenter prospective registrywill provide data to evaluate the prognostic impact of a number of patients' risk factors as well as the efficacy and safety of operative methods and drugs used during the pre-, peri- and postoperative period.
Interventions
PROCEDURECoronary artery bypass surgery
Patients will undergo coronary artery bypass grafting
Sponsors
Universita di Verona
Ospedali Riuniti Trieste
University of Catania
University of Leicester
Centre Hospitalier Universitaire de Besancon
Karolinska Institutet
San Camillo Hospital, Rome
Rennes University Hospital
S. Anna Hospital
Paracelsus Medical University
University of Campania Luigi Vanvitelli
University of Parma
University of Bari
Centro Cardiologico Monzino
University of Hamburg-Eppendorf
University of Genova
University of Oulu
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients of aged \> 18 years undergoing isolated CABG for stable coronary artery disease or acute coronary syndrome. Patients undergoing Maze procedure will be included in this registry.
Exclusion criteria
* Patients undergoing any other major cardiac surgery procedure will be excluded from this registry.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | The outcome measure will be assessed at time points up to 10 years after surgery | Any death occurring after surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prolonged use of inotropes | Participants will be followed for the duration of hospital stay (expected: 10 days) | Use of inotropes \> 12 hours after surgery |
| Intra-aortic balloon pump | Participants will be followed for the duration of hospital stay (expected: 10 days) | Use of intra-aortic balloon pump for acute heart failure after surgery |
| ECMO | Participants will be followed for the duration of hospital stay (expected: 10 days) | Use of extracorporeal membrane oxygenation for acute heart failure after surgery |
| Repeat revascularization | The outcome measure will be assessed at time points up to 10 years after surgery | Any repeat myocardial revascularization procedure performed after surgery |
| Wound infection | Participants will be followed up for 3 months after surgery | Any deep sternal or lower limb wound infection occurring after surgery |
| Blood losses | Participants will be followed 12 hours after surgery | Amont of blood losses from drainages 12 hours after surgery |
| Nadir hematocrit | Participants will be followed during the operation day | Lowest hematocrit level during the operation day |
| Use of blood products | Participants will be followed for the duration of hospital stay (expected: 10 days) | Use of any blood product (red blood cell, fresh frozen plasma, Octaplas, platelets) during the in-hospital stay |
| Use of prothrombotic drugs | Participants will be followed for the duration of hospital stay (expected: 10 days) | Perioperative use of cryoprecipitate, PCC and/or rFVIIa for excessive bleeding PCCs Perioperative use of rFVIIa, PCC, cryoprecipitate |
| Stroke | The outcome measure will be assessed at time points up to 10 years after surgery | Any ischemic brain injury occurring after surgery and lasting \> 24 hours |
| Atrial fibrillation | Participants will be followed for the duration of hospital stay (expected: 10 days) | New episode of atrial fibrillation requiring or not cardioversion during the in-hospital stay |
| Renal replacement therapy | Participants will be followed for the duration of hospital stay (expected: 10 days) | Any renal replacement therapy during the in-hospital stay |
| Highest level of serum creatinine | Participants will be followed for the duration of hospital stay (expected: 10 days) | Highest level of serum creatinine during the in-hospital stay |
| Myocardial infarction | The outcome measure will be assessed at time point up to 10 years after surgery | Myocardial infarction (diagnosed by ECG and troponin monitoring) any time after surgery |
| Length of stay in the intensive care unit | Participants will be followed for the duration of hospital stay (expected: 10 days) | Length of stay in the intensive care unit after surgery |
| Pericardial effusion | Participants will be followed up to 3 months after surgery. | Pericardial effusion requiring medical or surgical treatment |
| Postoperative use of antibiotics | Participants will be followed for the duration of hospital stay (expected: 10 days) | Postoperative use of antibiotics for postoperative infection |
| Gastrointestinal complications | Participants will be followed for the duration of hospital stay (expected: 10 days) | Any gastrointestinal complication requiring medical or surgical treatment after surgery |
| Resternotomy for bleeding | Participants will be followed for the duration of hospital stay (expected: 10 days) | Re-exploration for excessive bleeding |
Countries
Finland
Contacts
Primary ContactFausto Biancari, Professor
Outcome results
None listed